In Brief: In vivo radiopharmaceuticals
This article was originally published in The Gray Sheet
In vivo radiopharmaceuticals: FDA will hold a public meeting Feb. 27 on developing regulations on the use of in vivo radiopharmaceuticals diagnosis and monitoring. The agency will be soliciting input from patient advocacy groups, physicians, industry and the public concerning the development of new regulations for the review of radiopharmaceutical applications as required by the FDA Modernization Act. Written comments are due March 4. The meeting will begin at 8:00 a.m. in Conference Rooms D and E of FDA's Parklawn building in Rockville, Maryland...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.